Niraparib+Abiraterone Suppliers & Bulk Manufacturers
Available Forms: Tablet
Available Strengths: 100mg+500mg / 200mg+1000mg
Reference Brands: AKEEGA (USA/EU)
Category:
Oncology Cancer Care
Niraparib/Abiraterone is an oral dual-action anticancer therapy used for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). Niraparib is a PARP inhibitor that blocks DNA repair in cancer cells, leading to cell death, while Abiraterone acetate inhibits androgen biosynthesis, reducing tumor growth driven by male hormones. The combination is taken once daily with prednisone and is designed to improve treatment efficacy by targeting cancer through two complementary mechanisms. It is available as film-coated tablets in varying strengths.
Niraparib+Abiraterone is available in Tablet
and strengths such as 100mg+500mg / 200mg+1000mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Niraparib+Abiraterone is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Niraparib+Abiraterone can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing